Arcturus Therapeutics AI Stock Analysis
Want to see ARCT full AI Analyst Report?
Arcturus Therapeutics (ARCT) AI Stock Analysis
Arcturus Therapeutics
(NASDAQ:ARCT)
ARCT scores below average primarily due to weak financial performance (ongoing losses and negative free cash flow) and bearish technicals (price below major moving averages with negative MACD). Partially offsetting these are constructive earnings-call updates on clinical progress and runway through 2028, plus a supportive Meiji strategic investment at a large premium, while valuation remains constrained by unprofitability and no dividend support.
Arcturus Therapeutics (ARCT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $239.51M
- Dividend Yield
- ―
- Average Volume (3M)
- 993.01K
- Price to Earnings (P/E)
- -2.7
- Beta (1Y)
- 2.26
- Revenue Growth
- -74.84%
- EPS Growth
- -25.04%
- Country
- US
- Employees
- 109
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Arcturus Therapeutics Business Overview & Revenue Model
Company Description
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its nota...
How the Company Makes Money
Arcturus primarily makes money through (1) collaboration and licensing arrangements and (2) to a lesser extent, other operating revenues typical of clinical-stage biopharma companies; it may also generate interest income from its cash and investments...
Arcturus Therapeutics Earnings Call Summary
The call was predominantly positive, with encouraging ARCT-810 clinical data, a reported 38-fold LUNAR 2.0 potency improvement, progress in the ARCT-032 and ARCT-2601 programs, expanding pipeline capabilities and a cash runway through year-end 2028. The main negatives were the significant year-to-date revenue decline, higher year-to-date net loss, reduced cash balance and uncertainty around the timing of a potential ARCT-032 Phase III start.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Arcturus expects enrollment in the ARCT-032 Phase II study to be completed by year-end, with Cohort 4 evaluating 10 milligrams administered by inhalation for 12 weeks in up to 20 adults, primarily Class I CF subjects, full Cohort 4 data planned for presentation in the second quarter of 2027, and CF top line data available before the full data presentation; the go/no-go decision timing has not been guided. The company plans to initiate Phase II dosing of ARCT-2601 in the first quarter of 2027, enrolling upwards to 6 subjects ages 12 and older, with top line data in the second half of 2027 and the starting dose being a dose previously tested with 810. Arcturus currently plans to submit an IND for its PKU program in the second half of 2027, expects commercial activities for KOSTAIVE in Europe and the United Kingdom in 2027 while pursuing a partner for the U.S. region, and expects its cash runway to extend through year-end 2028.
Arcturus Therapeutics Financial Statement Overview
Summary
Overall fundamentals are pressured by persistent losses and cash burn: TTM net loss (~-$78.1M) and negative operating/free cash flow (~-$62.6M) indicate the business is not self-funding. The balance sheet is a relative bright spot with low leverage (~0.11x debt-to-equity), but equity/assets have been trending down and ROE is deeply negative, signaling ongoing capital consumption.
Income Statement
24NegativeBalance Sheet
63PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.95M | 67.22M | 138.39M | 157.75M | 205.75M | 12.36M |
| Gross Profit | 24.29M | 64.20M | 138.39M | 157.75M | 205.75M | 12.36M |
| EBITDA | -77.00M | -62.76M | -77.40M | -24.16M | 15.17M | -199.81M |
| Net Income | -87.24M | -65.78M | -80.94M | -29.73M | 9.35M | -203.67M |
Balance Sheet | ||||||
| Total Assets | 215.32M | 271.15M | 344.07M | 429.40M | 450.39M | 392.81M |
| Cash, Cash Equivalents and Short-Term Investments | 184.82M | 230.91M | 237.03M | 292.00M | 391.88M | 370.49M |
| Total Debt | 21.86M | 25.00M | 28.55M | 30.22M | 94.75M | 69.15M |
| Total Liabilities | 46.59M | 57.16M | 103.09M | 150.89M | 180.07M | 164.60M |
| Stockholders Equity | 168.73M | 213.99M | 240.98M | 278.51M | 270.31M | 228.21M |
Cash Flow | ||||||
| Free Cash Flow | -62.67M | -74.50M | -60.40M | -21.00M | 24.27M | -138.45M |
| Operating Cash Flow | -62.48M | -74.27M | -59.75M | -18.10M | 31.99M | -135.04M |
| Investing Cash Flow | 87.34K | -230.00K | -648.00K | -2.90M | -7.73M | -3.41M |
| Financing Cash Flow | 11.99M | 13.38M | 5.42M | -24.09M | -2.86M | 48.02M |
Arcturus Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARCT, the sentiment is Negative. The current price of 8.31 is below the 20-day moving average (MA) of 10.10, below the 50-day MA of 12.28, and below the 200-day MA of 9.11, indicating a bearish trend. The MACD of -0.95 indicates Positive momentum. The RSI at 36.74 is Neutral, neither overbought nor oversold. The STOCH value of 5.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARCT.
Arcturus Therapeutics Risk Analysis
Arcturus Therapeutics disclosed 63 risk factors in its most recent earnings report. Arcturus Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksArcturus Therapeutics Peers Comparison
Overall Rating
KRRO55Neutral
ARCT49Neutral
SLN48Neutral
EDIT47Neutral
BNTC45Neutral
PRQR42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | $174.45M | -1.42 | -117.05% | ― | -82.47% | 3.73% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $239.52M | -2.72 | -46.79% | ― | -74.84% | -25.04% | |
| 48Neutral | $1.23B | -7.26 | -56.32% | ― | ― | ― | |
| 47Neutral | $288.62M | -3.08 | -130.43% | ― | 7.43% | 74.00% | |
| 45Neutral | $308.46M | -8.45 | -27.60% | ― | ― | -12.64% | |
| 42Neutral | $166.52M | -2.84 | -70.45% | ― | 19.49% | -4.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ARCT | Arcturus Therapeutics | 8.31 | 2.27 | 37.58% | |
| PRQR | ProQR Therapeutics BV | 1.18 | -0.85 | -41.87% | |
| BNTC | Benitec Biopharma | 8.54 | -4.56 | -34.81% | |
| EDIT | Editas Medicine Inc. | 1.87 | -0.65 | -25.79% | |
| KRRO | Korro Bio, Inc. | 12.71 | 6.30 | 98.28% | |
| SLN | Silence Therapeutics Plc | 19.80 | 13.37 | 207.93% |
Arcturus Therapeutics Corporate Events
Arcturus Expands Meiji Collaboration Through $50 Million Investment
PositiveOn November 16, 2026, Arcturus entered a securities purchase agreement selling Meiji 2,466,395 shares for $50.0 million at $20.27 per share, an 80% premium to the average closing price over the 30 trading days through and including November 11; the s...
Arcturus Showcases Phase 2 ARCT-810 Data, mRNA Advances
PositiveOn September 23, 2026, Arcturus Therapeutics presented an overview of Phase 2 clinical data for its investigational therapy ARCT-810 and provided an update on its mRNA delivery platform. The company also issued a press release summarizing these mater...
Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium
PositiveOn August 25, 2026, Arcturus Therapeutics will present a poster on ARCT-810, its mRNA therapy candidate for ornithine transcarbamylase deficiency, at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism in Helsinki, F...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 16, 2026
